What is ARIAD Pharmaceuticals Gross-Profit-to-Asset %?
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. ARIAD Pharmaceuticals's annualizedGross Profit for the quarter that ended in Sep. 2016 was $179.5 Mil.
ARIAD Pharmaceuticals's average Total Assets over the quarter that ended in Sep. 2016 was $650.5 Mil. Therefore, ARIAD Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2016 was 27.60%.
ARIAD Pharmaceuticals Gross-Profit-to-Asset % Historical Data
The historical data trend for ARIAD Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ARIAD Pharmaceuticals's Gross-Profit-to-Asset %
For the Biotechnology subindustry, ARIAD Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARIAD Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARIAD Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where ARIAD Pharmaceuticals's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Sep. 2016) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
ARIAD Pharmaceuticals Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description
ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARIA has been successfully added to your 